Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: A multicenter, double-blind, placebo-controlled trial

Archives of Internal Medicine

Volumn 157, Issue 3, 1997, Pages 343-349

  Mertz, Gregory J ^a   Loveless, Mark O ^b   Levin, Myron J ^c   Kraus, Stephen J ^d   Fowler, Sandra L ^e   Goade, Diane ^a   Tyring, Stephen K ^f  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Children's Hospital Colorado   (United States)

^d Georgia Clinical Research Center   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAMCICLOVIR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENITAL HERPES; HEADACHE; HERPES SIMPLEX; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENSTRUATION DISORDER; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0031030411     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.3.343     Document Type: Article

References (35)

1. Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. 1983;98:958-972.
2. VanderPlate C, Aral SO. Psychosocial aspects of genital herpes virus infection. Heath Psychol. 1987;6:57-72.
3. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med. 1992;116:197-202.
4. Mertz GJ, Coombs RW, Ashley R, et al. Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: a prospective study. J Infect Dis. 1988;157:1169-1177.
5. Mertz GJ, Schmidt O, Jourden JL, et al. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis. 1985;12:33-39.
6. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med. 1995;333:770-775.
7. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med. 1996;124:8-15.
8. Mertz GJ, Jones CC, Mills J, et al. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection: a multicenter double-blind trial. JAMA. 1988;260:201-206.
9. Douglas JM, Critchlow C, Benedetti J, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med. 1984;310:1551-1556.
10. Straus SE, Takiff HE, Seidlin M, et al. Suppression of frequently recurring genital herpes: a placebo-controlled, double-blind trial of oral acyclovir. N Engl J Med. 1984;310:1545-1550.
11. Mindel A, Faherty A, Carney O, Patou G, Freris M, Williams P. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet. 1988;1:926-928.
12. Fife KH, Crumpacker CS, Mertz GJ, Hill EC, Boone GS, the Acyclovir Study Group. Recurrence and resistance patterns of herpes simplex following cessation of more than 6 years of chronic acyclovir suppression. J Infect Dis. 1994;169:1338-1341.
13. de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983;12(suppl B):29-37.
14. Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpes agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine; penciclovir]. Antimicrob Agents Chemother. 1989;33:1765-1773.
15. Pue M, Benet LZ. Pharmacokinetics of famciclovir in man. Antiviral Chem Chemother. 1993;4(suppl):47-55.
16. Boyd MR. Update on famciclovir. In: Mills J, Corey L, eds. Antiviral Chemotherapy: New Directions for Clinical Application and Research. Englewood Cliffs, NJ: Prentice Hall International Inc; 1989;3:83-96.
17. Boyd MR, Safrin S, Kern ER. Penciclovir: a review of the spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem Chemother. 1993;4 (suppl):3-11.
18. Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, Perkins RM, Vere Hodge RA. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV 1), HSV 2, and varicella-zoster virus. Antimicrob Agents Chemother. 1992;36:2747-2757.
19. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia, a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:89-96.
20. Sacks SL, Aoki FY, Diaz-Mitoma F, et al. Patient-initiated treatment of recurrent genital herpes with oral famciclovir. In: Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; October 5, 1994; Orlando, Fla.
21. Loveless M, Harris W, Sacks S. Treatment of first episode genital herpes with famciclovir. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; September 18, 1995; San Francisco, Calif.
22. Goldstein LC, Corey L, McDougall JK, Tolentino E, Nowinski RC. Monoclonal antibodies to herpes simplex viruses: use in antigenic typing and rapid diagnosis. J Infect Dis. 1983;147:829-837.
23. Rabalais G, Levin MJ, Berkowitz FE. Rapid herpes simplex virus susceptibility testing using an enzyme-linked immunosorbent assay performed in situ on fixed virus-infected monolayers. Antimicrob Agents Chemother. 1987;31:946-948.
24. Weinberg A, Bate BJ, Masters HB, et al. In vitro activities of penciclovir and acyclovir against herpes simplex types 1 and 2. Antimicrob Agents Chemother. 1992;36:2037-2038.
25. Goade D, Bell R, Yamada T, Mertz GJ, Jenison S. Locations of herpes simplex virus type 2 (HSV 2) glycoprotein B (gB) epitopes recognized by human serum immunoglobulin-G (IgG) antibodies. J Virol. 1996;70:2950-2956.
26. Jenison SA, Firzlaff JM, Langenberg A, Galloway DA. Identification of immunoreactive antigens of human papillomavirus type 6b by using Escherichia coli-expressed fusion proteins. J Virol. 1988;62:2115-2123.
27. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800-802.
28. Field HJ, Tewari D, Sutton D, Thackray AM. Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model. Antimicrob Agents Chemother. 1995;39:1114-1119.
29. Thackray AM, Field HJ. Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. J Infect Dis. 1996;173:291-299.
30. Sacks SL, Bishop AM, Fox R, Lee GCY. A double-blind, placebo-controlled trial of the effect of chronically administered oral famciclovir on sperm production in men with recurrent genital herpes infection. Antiviral Res. 1994;23(suppl 1):72.
31. Diaz-Mitoma F, Sibbald RG, Shafran SD, and The Collaborative Ganciclovir Genital Herpes Research Group. Famciclovir in suppression of recurrent genital herpes: results of a multinational study. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; New Orleans, La; September 18, 1996. Abstract 111.
32. Douglas JM, Davis LG, Remington ML, et al. A double-blind, placebo-controlled trial of the effect of chronically administered oral acyclovir on sperm production in men with frequently recurrent genital herpes. J Infect Dis. 1988;157:588-593.
33. Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with zoster and genital herpes. Antimicrob Agents Chemother. 1994;38:2454-2457.
34. Nusinoff Lehrman S, Douglas JM, Corey L, Barry DW. Recurrent genital herpes and suppressive oral acyclovir therapy: relationship between clinical out-come and in vitro drug sensitivity. Ann Intern Med. 1986;104:786-790.
35. Kost RG, Hill EL, Tigges M, Straus SE. Recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med. 1993;329:1777-1782.